KRON: Kronos Bio, Inc. Stock

by  •  • Comments Off on KRON: Kronos Bio, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 57.34
Enterprise Value ($M) -17.62
Book Value ($M) 111.13
Book Value / Share 1.84
Price / Book 0.52
NCAV ($M) 89.02
NCAV / Share 1.48
Price / NCAV 0.64

Profitability (mra)
Return on Invested Capital (ROIC) -0.63
Return on Assets (ROA) -0.40
Return on Equity (ROE) -0.54

Liquidity (mrq)
Quick Ratio 8.32
Current Ratio 8.32

Balance Sheet (mrq) ($M)
Current Assets 127.92
Assets 150.02
Liabilities 38.90
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Omega Fund V, L.P. 0.00 -100.00
07-02 13D/A Bischofberger Norbert W 21.10 -10.39

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-14 9,120 205,280 4.44
2025-01-13 15,479 227,668 6.80
2025-01-10 61,711 270,364 22.83

(click for more detail)

Similar Companies
KMDA – Kamada Ltd. KNSA – Kiniksa Pharmaceuticals, Ltd.
KPTI – Karyopharm Therapeutics Inc. KRYS – Krystal Biotech, Inc.
KURA – Kura Oncology, Inc.


Financial data and stock pages provided by
Fintel.io